Insights into the uses of ibrutinib for patients with Waldenström’s macroglobulinemia

Ramón Garcia Sanz, MD, PhD, Hospital Universitario de Salamanca, Salamanca, Spain, discusses the use of ibrutinib, a BTK inhibitor, in the treatment of patients with Waldenström's macroglobulinemia (WM). Ibrutinib has shown the best response rates in WM after chemoimmunotherapy and can be used as a first-line treatment when chemoimmunotherapy is not manageable. It does, however, have side effects such as arrhythmias and hypertension, which can be hard to manage. Research is therefore being conducted to mitigate these toxicities. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.